Establishment and Characterization of Dedifferentiated Chondrosarcoma Cell Line and Effect of Mutant IDH1 inhibitor

被引：0
|
作者：
Saisuwan, Krittamate [1 ]
Seiji, Okada [2 ]
Boonnate, Piyanard [3 ]
Rumi, Nakagawa [4 ]
Tohru, Hirozane [1 ]
Kazutaka, Kikuta [1 ]
机构：
[1] Tochigi Canc Ctr, Div Musculoskeletal Oncol Orthopaed Surg, Utsunomiya, Tochigi, Japan
[2] Kumamoto Univ, Div Hematopoiesis, Kumamoto, Japan
[3] Chulabhorn Res Inst, Lab Environm & Toxicol, Bangkok, Thailand
[4] Tochigi Canc Ctr, Div Diagnost Patho, Utsunomiya, Tochigi, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3099
引用
收藏
页码：1628 / 1628
页数：1
相关论文
共 50 条
  • [21] A NOVEL PEDIATRIC IDH1 MUTANT GLIOBLASTOMA CELL LINE AND XENOGRAFT MODEL
    Metselaar, Dennis
    Meel, Michael
    Waranecki, Piotr
    Zwaan, Kenn
    Poddighe, Pino
    van Vuurden, Dannis
    Kaspers, Gertjan
    Hulleman, Esther
    NEURO-ONCOLOGY, 2018, 20 : 185 - 185
  • [22] Depletion of mutant IDH1 impairs chondrosarcoma growth by downregulating integrins.
    Li, Luyuan
    Hu, Xiaoyu
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] IDH-mutant glioma: A new IDH1 inhibitor moves forward
    Miller, Julie J.
    Arrillaga-Romany, Isabel
    NEURO-ONCOLOGY, 2023, 25 (02) : 337 - 338
  • [24] Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
    Davis, Mindy I.
    Gross, Stefan
    Shen, Min
    Straley, Kimberly S.
    Pragani, Rajan
    Lea, Wendy A.
    Popovici-Muller, Janeta
    DeLaBarre, Byron
    Artin, Erin
    Thorne, Natasha
    Auld, Douglas S.
    Li, Zhuyin
    Dang, Lenny
    Boxer, Matthew B.
    Simeonov, Anton
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (20) : 13717 - 13725
  • [25] Recent advances of IDH1 mutant inhibitor in cancer therapy
    Tian, Wangqi
    Zhang, Weitong
    Wang, Yifan
    Jin, Ruyi
    Wang, Yuwei
    Guo, Hui
    Tang, Yuping
    Yao, Xiaojun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
    Popovici-Muller, Janeta
    Lemieux, Rene M.
    Artin, Erin
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Travins, Jeremy
    Cianchetta, Giovanni
    Cai, Zhenwei
    Zhou, Ding
    Cui, Dawei
    Chen, Ping
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    David, Muriel D.
    Penard-Lacronique, Virginie
    Quivoron, Cyril
    Saada, Veronique
    De Botton, Stephane
    Gross, Stefan
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Kim, Hyeryun
    Jin, Shengfang
    Gu, Zhiwei
    Yao, Gui
    Luo, Zhiyong
    Lv, Xiaobing
    Fang, Cheng
    Yan, Liping
    Olaharski, Andrew
    Silverman, Lee
    Biller, Scott
    Su, Shin-San M.
    Yen, Katharine
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
  • [27] Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors
    Fer, Nicole D.
    Harris, Erik
    Fox, Stephen
    Zhou, Ming
    Simpson, Catherine
    Liu, Jing
    Korboukh, Ilia
    Hull-Ryde, Emily A.
    Janzen, William P.
    Frye, Stephen V.
    Monks, Anne
    Teicher, Beverly
    Rapisarda, Annamaria
    CANCER RESEARCH, 2014, 74 (19)
  • [28] Diagnostic Utility of IDH1/2 Mutation To Distinguish Dedifferentiated Chondrosarcoma from Undifferentiated Pleomorphic Sarcoma
    Chen, Shaoxiong
    Fritchie, Karen
    Wei, Shi
    Curless, Kendra
    Post, Kristin
    Cheng, Liang
    LABORATORY INVESTIGATION, 2016, 96 : 15A - 15A
  • [29] Diagnostic Utility of IDH1/2 Mutation To Distinguish Dedifferentiated Chondrosarcoma from Undifferentiated Pleomorphic Sarcoma
    Chen, Shaoxiong
    Fritchie, Karen
    Wei, Shi
    Curless, Kendra
    Post, Kristin
    Cheng, Liang
    MODERN PATHOLOGY, 2016, 29 : 15A - 15A
  • [30] Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
    Shibata, Tatsuhiro
    Kokubu, Akiko
    Miyamoto, Masashi
    Sasajima, Yuko
    Yamazaki, Naoya
    AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (03): : 1395 - 1402
12345